Evaluation of Lipid profile and Uric acid level in Type II Diabetes mellitus

T2DM is characterized primarily by pancreatic beta cell loss, inadequate insulin production, or insulin resistance in body cells, among other causes. T2DM is related to a variety of other indications and symptoms including coronary heart disease, kidney illness, eye abnormalities, peripheral vascular disease, digestive system diseases, high blood pressure and depression. Lipid abnormalities are common in persons with type 2 diabetes and prediabetes, although the pattern of the different lipids may vary between ethnic groups, economic levels and access to health care. Uric acid is produced during nucleotide and adenosine triphosphate (ATP) metabolism and is the end product of human purine. Biologically, uric acid plays a significant role in developing insulin resistance in animal models by reducing the bioavailability of nitric oxide which is required for insulin-stimulated glucose uptake. This study aimed to evaluate the lipid profile and uric acid level in patients with Type 2 diabetes mellitus. Blood samples were collected from 50 control and diabetic patients. The lipid profile and uric acid level were estimated by the kit method. Significantly higher levels of total cholesterol, triglycerides, HDL and LDL were observed in the diabetic group compared to the controls. Significantly low levels of serum uric acid and higher blood glucose levels were observed between normal and diabetic subjects. Diabetic dyslipidemia is curable if identified early. It can be improved by regulating glycemic (glucose) levels, lowering free fatty acids and increasing VLDL production by the liver. It can also be treated with weight loss, exercise, smoking cessation, a nutritious diet and pharmaceutical therapy.